Genenta Science S.p.A (GNTA) Receivables (2024 - 2025)
Genenta Science S.p.A (GNTA) posted Receivables of $5820.2 for Q4 2025, up 2.83% sequentially from $5659.8 in Q2 2025, and up 8.93% YoY from $5343.0 in Q4 2024.
Genenta Science S.p.A (GNTA) Receivables (2024 - 2025) Analysis & Trends
Genenta Science S.p.A has reported Receivables for 2 years, with the latest figure at $5820.2 in Q4 2025.
- Quarterly Receivables rose 8.93% year-over-year to $5820.2 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5820.2 (up 8.93% YoY) and the FY2025 annual result came in at $5820.2, up 8.93% from the prior year.
- Receivables advanced to $5820.2 in Q4 2025 per GNTA's latest filing, from $5659.8 in the prior quarter.
- Over five years, Receivables peaked at $5820.2 in Q4 2025 and troughed at $5343.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Genenta Science S.p.A | 23.36 Mn | -35.73 Mn | - | 5,820.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5,820.22 |
| Jun 30, 2025 | 5,659.80 |
| Dec 31, 2024 | 5,342.98 |
| Jun 30, 2024 | 5,384.44 |